These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 16924941)

  • 21. [Cardiovascular risk assessment for the use of ADHD drugs in children].
    Berg A; Bråtane E; Odland HH; Brudvik C; Rosland B; Hirth A
    Tidsskr Nor Laegeforen; 2014 Apr; 134(7):710-4. PubMed ID: 24721858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Encouraging news about ADHD drugs and heart risk in adults.
    Harv Ment Health Lett; 2012 Mar; 28(9):7. PubMed ID: 22474711
    [No Abstract]   [Full Text] [Related]  

  • 23. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
    Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytogenetic effects in children treated with methylphenidate.
    El-Zein RA; Abdel-Rahman SZ; Hay MJ; Lopez MS; Bondy ML; Morris DL; Legator MS
    Cancer Lett; 2005 Dec; 230(2):284-91. PubMed ID: 16297714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ADHD drugs and cardiovascular risk.
    Nissen SE
    N Engl J Med; 2006 Apr; 354(14):1445-8. PubMed ID: 16549404
    [No Abstract]   [Full Text] [Related]  

  • 26. Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder.
    Silva RR; Skimming JW; Muniz R
    Clin Pediatr (Phila); 2010 Sep; 49(9):840-51. PubMed ID: 20693523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risperidone-to-methylphenidate switch reaction in children: three cases.
    Sabuncuoglu O
    J Psychopharmacol; 2007 Mar; 21(2):216-9. PubMed ID: 17329303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder.
    Olfson M; Huang C; Gerhard T; Winterstein AG; Crystal S; Allison PD; Marcus SC
    J Am Acad Child Adolesc Psychiatry; 2012 Feb; 51(2):147-56. PubMed ID: 22265361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment.
    Torres AR; Whitney J; Gonzalez-Heydrich J
    Epilepsy Behav; 2008 Feb; 12(2):217-33. PubMed ID: 18065271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.
    Hammerness PG; Perrin JM; Shelley-Abrahamson R; Wilens TE
    J Am Acad Child Adolesc Psychiatry; 2011 Oct; 50(10):978-90. PubMed ID: 21961773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Children's self-reports on perceived effects on taking stimulant medication for ADHD.
    Thorell LB; Dahlström K
    J Atten Disord; 2009 Mar; 12(5):460-8. PubMed ID: 18685139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
    Perrin JM; Friedman RA; Knilans TK; ;
    Pediatrics; 2008 Aug; 122(2):451-3. PubMed ID: 18676566
    [No Abstract]   [Full Text] [Related]  

  • 33. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.
    Walitza S; Kämpf K; Artamonov N; Romanos M; Gnana Oli R; Wirth S; Warnke A; Gerlach M; Stopper H
    Toxicol Lett; 2009 Jan; 184(1):38-43. PubMed ID: 19015014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcomes of stimulant medication in attention-deficit hyperactivity disorder.
    Poulton A
    Expert Rev Neurother; 2006 Apr; 6(4):551-61. PubMed ID: 16623654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-related quality of life in methylphenidate-treated children with attention-deficit-hyperactivity disorder: results from a Taiwanese sample.
    Yang P; Hsu HY; Chiou SS; Chao MC
    Aust N Z J Psychiatry; 2007 Dec; 41(12):998-1004. PubMed ID: 17999272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medications for adolescents with attention-deficit/hyperactivity disorder.
    Soileau EJ
    Adolesc Med State Art Rev; 2008 Aug; 19(2):254-67, viii-ix. PubMed ID: 18822831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ECGs before stimulants in children.
    Med Lett Drugs Ther; 2008 Jul; 50(1291):60. PubMed ID: 18654112
    [No Abstract]   [Full Text] [Related]  

  • 38. ADHD drugs and cardiovascular risk.
    Rappley MD; Moore JW; Dokken D
    N Engl J Med; 2006 May; 354(21):2296-8; author reply 2296-8. PubMed ID: 16729375
    [No Abstract]   [Full Text] [Related]  

  • 39. Absence of cytogenetic effects in children and adults with attention-deficit/hyperactivity disorder treated with methylphenidate.
    Ponsa I; Ramos-Quiroga JA; Ribasés M; Bosch R; Bielsa A; Ordeig MT; Morell M; Miró R; de Cid R; Estivill X; Casas M; Bayés M; Cormand B; Hervás A
    Mutat Res; 2009 Jun; 666(1-2):44-9. PubMed ID: 19457516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Apropos the National Board and Welfare's report on ADDH: some views on the treatment with central nervous system stimulants].
    Zetterström R
    Lakartidningen; 2002 Aug; 99(35):3435-6. PubMed ID: 12362770
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.